HC Wainwright Has Pessimistic Outlook of COLL Q1 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Collegium Pharmaceutical in a note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will post earnings of $1.20 per share for the quarter, down from their previous forecast of $1.29. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

A number of other analysts have also recently commented on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday, January 10th. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Trading Down 1.3 %

Shares of Collegium Pharmaceutical stock opened at $30.15 on Wednesday. Collegium Pharmaceutical has a 12-month low of $27.28 and a 12-month high of $42.29. The firm’s 50 day simple moving average is $30.57 and its two-hundred day simple moving average is $32.54. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $949.30 million, a price-to-earnings ratio of 13.00 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. New Age Alpha Advisors LLC acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at $40,000. TD Private Client Wealth LLC raised its position in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. KBC Group NV lifted its stake in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after buying an additional 982 shares in the last quarter. Virtus Fund Advisers LLC boosted its position in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.